Objective-Atrial fibrillation (AF) patients experience adverse cardiovascular events (ACEs) despite anticoagulant therapy. We reported that rs2431697 of miR-146a, a negative regulator of inflammation, predicts ACEs in patients with AF. The relationship between neutrophil extracellular traps and thrombogenesis is known. Thus, our aim was to evaluate the role of neutrophil extracellular trap compounds as prognostic markers of ACEs in AF and to study whether miR-146a affects NETosis. Approach and Results-We included 336 steadily anticoagulated AF patients with a median follow-up of 7.9 years (interquartile range, 7.3-8.1) and 127 healthy subjects. The reviewed ACEs included stroke (ischemic/embolic), acute coronary syndrome, acute heart failure, and global or vascular death. We quantified cell-free DNA and NE (neutrophil elastase) at diagnosis. Rs2431697 was genotyped. Neutrophils from human and mice were seeded to analyze shed cellfree DNA and H3cit (citrullinated histone 3) after activation. In human plasmas, higher NE levels (>55.29 ng/mL), but not cell-free DNA, were independently associated with higher risk of all-cause mortality (hazard ratio, 2.24; 95% CI, 1.36-3.68), cardiovascular mortality (hazard ratio, 4.77; 95% CI, 1.11-20.47), and composite cardiovascular events (hazard ratio, 1.84; 95% CI, 1.01-3.76). In patients, NE levels were associated with rs2431697 (TT: 51.82±2.73 versus CC: 40.01±3.05 ng/mL; P=0.040). In vitro, both human (TT for rs2431697) and miR-146a −/− mice neutrophils yielded higher levels of cell-free DNA and H3cit than CC or wild-type cells, respectively. Conclusions-NE activity can provide new ACE prognostic information in AF patients. These findings provide evidence of a potential role of miR-146a in neutrophil extracellular trap generation and cardiovascular risk in AF. Visual Overview-An online visual overview is available for this article. Arroyo et al
A trial fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with a 5-fold increase in the risk of stroke and thromboembolism, which results in an increased morbidity and mortality. 1 Classical atherosclerotic risk factors usually underlie such complications, as well as peripheral artery disease or aortic plaque, thus contributing to an increased risk of stroke. 2 Thus, atherosclerosis and AF are interweaved 3 such that vascular disease is included in the CHA 2 DS 2 -VASc (cardiac failure or dysfunction, hypertension, age ≥75 [doubled], diabetes, stroke [doubled] -vascular disease, age 65-74 y and sex category [female]) score for stroke risk stratification. 4, 5 This score is currently recommended by the American and European guidelines to assess the suitability of thromboprophylaxis with oral anticoagulation in patients with AF. Nonetheless, adverse cardiovascular events (ACEs) in AF-anticoagulated patients have been estimated to be ≈4%. 6, 7 Previous results from our group demonstrated that lower levels of miR-146a, guided by the T variant of rs2431697, are predictors of ACEs in AF patients. 8 MiR-146a is a negative regulator in innate and inflammatory immune responses through the NF (nuclear factor)-κB pathway, in which its mediators, TLR4 (Toll-like receptor 4), IRAK1 (interleukin-1 receptor-associated kinase 1), and TRAF6 (TNF receptorassociated factor 6), are miR-146a targets. 9, 10 Our findings are in accordance with the new concept of atherosclerosis, which is currently considered a result of a codriven interplay between chronic damage of the intima and the nonresolved inflammation that occurs in response to such injury. 11, 12 In this work, we investigated the molecular role of miR-146a in the development of ACEs in AF patients. This miRNA is mainly expressed in immune cells, which are one of the main protagonists of thrombogenesis. 13, 14 Thus, the infiltration of activated monocytes/neutrophils in arteries mediates an overactivation of the immune system. 15 In addition, findings show that neutrophils shed neutrophil extracellular traps (NETs), which consist of cell-free DNA (cfDNA), histones, NE (neutrophil elastase), and myeloperoxidase that trigger the coagulation and inflammation underlying cardiovascular complications. [16] [17] [18] NET burden has even been described as a predictor of ST-segment resolution and myocardial infarct size, 17 as well as being associated with autoimmune disorders and their thrombotic complications. 19 Indeed, in a large-scale study, NETs have been histologically located in aspirated thrombi of patients with stent thrombosis, supporting their pathophysiological role in this process. 20 In this framework, the control of the inflammatory environment in patients with AF is a field for promising, novel therapies. 15, 21 To date, there is no information on how mir-146a levels can affect the NETosis process. In this work, we intend to study the link between miR-146a and NETosis in relation to the occurrence of ACEs in patients with AF.
Materials and Methods

Patients
We included both healthy subjects and AF patients in this study. Healthy participants were white, unrelated volunteers from our local blood donor center. None of the healthy participants had a documented history of vascular disease, a personal history of thromboembolic/hemorrhagic disease or cancer.
Detailed data from AF patients have been previously reported. 8 In brief, consecutive patients with permanent or paroxysmal AF who were stable on acenocoumarol treatment (international normalized ratio [INR], 2.0-3.0) were recruited from our outpatient anticoagulation clinic. Follow-up information was obtained from routine visits to the anticoagulation clinic, from hospital electronic medical records, or when these were unavailable, by telephone interview. The investigators identified, confirmed, and recorded all adverse events.
All subjects who met eligibility criteria were enrolled after providing written informed consent. The study was approved by the Ethical Committee of our institution and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its subsequent amendments.
End Points
As primary ACE end points, we included ischemic stroke, all-cause mortality, cardiovascular mortality, and a combined end point of ACEs (the composite of stroke/transient ischemic attack, acute coronary syndrome, acute heart failure, or cardiovascular death). Ischemic stroke was defined as the sudden onset of a focal neurological deficit in a location consistent with the territory of a major cerebral artery and the result of an obstruction documented by imaging, surgery, or autopsy. Cardiovascular mortality was defined as death caused by sudden death, progressive congestive heart failure and fatal myocardial infarction, or a procedure-related death.
Patients' Samples and Reagents
At inclusion, blood samples were drawn atraumatically and without stasis into tubes preloaded with trisodium citrate (0.011 mol/L). Platelet-poor plasma fractions were obtained by centrifugation at 4°C for 20 minutes at 2200g. Aliquots were stored at −80°C to allow batch analysis. Plasma cfDNA was quantified with Sytox Green (ThermoFisher, Madrid, Spain). Briefly, a standard curve with DNA from salmon sperm (Sigma-Aldrich, Madrid, Spain) was generated for each determination, and plasma samples (10 µL) were assayed in triplicate. After 15 minutes in the dark, the plate was read at 488 nm in a microplate reader (Biotek Sinergy Ht, Izasa, Barcelona, Spain). The pooled plasma from 40 healthy volunteers was used as a reference.
Levels of NE from plasma were measured with a commercial ELISA (Abcam, Cambridge, UK) following the manufacturer's instructions. All samples were tested in duplicate.
Plasma vWF (von Willebrand factor) antigen levels were assessed in an automated coagulometer ACL Top 3G (Instrumentation Laboratory, Lexington, MA).
hsIL6 (high-sensitivity interleukin-6) levels were assessed by electrochemiluminescence in an automated analyzer (Cobas e601; Roche Diagnostica, Mannheim, Germany).
Genotyping
MIR-146A SNP rs2431697 was genotyped by Taqman analysis, using Taqman SNP Genotyping Assays C__26693319_10 (ThermoFisher). All genotypes were confirmed by sequencing of randomly selected samples.
Isolation of Human Neutrophils
Neutrophils were purified from whole blood of healthy donors, selected by rs2431697 genotype, on Histopaque 1077 (Sigma-Aldrich). The neutrophil pellet was finally resuspended in Hanks balanced salt solution (supplemented with Ca 2+ and Mg
2+
; ThermoFisher). Cells were counted by means of an automatic cell counter (BioRad, Hercules, CA). Purity was checked by flow cytometry and was always >90% (not shown).
Quantification of MiR-146a Expression
MiR-146a expression in human neutrophils was measured by qRT-PCR (real-time quantitative reverse transcription PCR) using 100 ng of total RNA with MultiScribe Reverse Transcriptase (ThermoFisher) and Premix Ex Taq (Probe qPCR) Master Mix (Takara Bio Company, Condalab, Madrid, Spain). Polymerase chain reaction of miR-146a and U6 (endogenous control) were performed using a Real Time LC480 PCR system (Roche Applied Science, Barcelona, Spain). The 2 -ΔCt method was used to calculate the relative abundance of mRNA compared with the expression of the endogenous control.
Mice
MiR-146a
−/− mice (The Jackson laboratory, Bar Harbor, ME) were backcrossed for >8 generations in a C57BL/6J background. Inbred wild-type (WT) littermates were used as controls to confront comparative studies. All the mice used in this study were 8 to 12 weeks of age. We included 4 females and 3 males because as far as we know, the miR-146a deficiency in mice affects both sexes equally. 
Nonstandard Abbreviations and Acronyms
Isolation of Murine Neutrophils
Primary bone marrow neutrophils were isolated from wild-type and miR-146a −/− mice. Briefly, bone marrow cells were collected by flushing the femur with Hanks balanced salt solution using a 26-gauge needle and filtering through a sterile 70-μm nylon cell strainer. Bone marrow single-cell suspensions were then washed with Hanks balanced salt solution, and primary bone marrow neutrophils were isolated by a negative selection technique (Neutrophil Isolation Kit, Miltenyi Biotec, Barcelona, Spain) and resuspended in Hanks balanced salt solution supplemented with EDTA/Mg 2+ . Neutrophil purity and viability >95% were checked by flow cytometry and propidium iodide, respectively (not shown).
In Vitro Neutrophil Activation
Purified human and mice neutrophils were seeded (600,000 cells/ well) in 12-well plates with 0.01% poly-l-lysine (Sigma-Aldrich) for quantification of the free DNA. In addition, 100 000 cells/well were seeded in 2% gelatin-treated coverslips to perform the immunofluorescence study. In both cases, cells were stimulated with 20 nmol/L phorbol-12-myristate-13-acetate (Sigma-Aldrich) in dimethyl sulfoxide. As a negative control of activation, the same number of cells was seeded in each case adding only dimethyl sulfoxide. Cells were incubated for 2 hours (murine neutrophils) or 4 hours (human neutrophils) at 37°C and 5% CO 2 .
Quantification of NETosis Markers From In Vitro Activated Neutrophils
DNA released from activated human and mice neutrophils was quantified, after MNaseI treatment (4×10 −3 U/mL) with Sytox Green (ThermoFisher), and fluorescence was detected as described previously.
H3cit (citrullinated histone 3) expression was quantified by immunofluorescence. For this, coverslips (n=6/sample) were blocked for 1 hour with 2% PBS-BSA and permeabilized with 0.5% PBS-BSA supplemented with 0.1% Triton X-100. Then, cells were incubated for 2 hours with 5 μg/mL anti-H3cit antibody (for citrulline R2, R8, and R17; Abcam). Alexa Fluor 546 antirabbit secondary antibody (ThermoFisher) was added. Next, coverslips were mounted with ProLong Gold Antifade medium with DAPI (4′, 6-diamino-2-phenylindole; ThermoFisher). The preparations were stored at 4°C until analysis.
Image capture was performed using a Leica-DMI6000B fluorescence microscope (Leica, Madrid, Spain). A minimum of 10 fields for each coverslip were captured. The image analysis was performed with ImageJ (https://imagej.nih.gov/ij/), and the ratio of H3cit-positive cells/total cells was calculated for each field.
Statistical Analysis
Categorical variables are expressed as frequencies and percentages. Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test and expressed as the mean±SEM or median and interquartile range (IQR), as appropriate. All statistical analyses were performed using parametric test for normally distributed data and nonparametric test for non-normally distributed data.
Differences in the means were assessed by Student t test or the Mann-Whitney U test, as appropriate, whereas correlations were tested using the statistical Spearman ρ. For multiple comparisons, 1-way ANOVA on ranks with a post hoc test (Bonferroni correction) were used. The χ 2 test was used to compare frequencies. Cox models were performed to determine the association between clinical risk factors, NE, and ACEs. The independent effect of each variable on prognosis was calculated using Cox proportional hazards regression models, incorporating into the multivariate model only those values that showed P<0.15 in the univariate analysis. The cutoff point of each biomarker with the best specificity and sensitivity was chosen using receiver-operating characteristic (ROC) curves.
We performed ROC curves to compare the predictive ability (assessed as C index) of the CHA 2 DS 2 -VASc score with a modified CHA 2 DS 2 -VASc score that included the NE. The comparison of both ROC curves was performed by the method of DeLong et al. 22 Finally, the increment of the predictive performance was also tested by the integrated discriminatory improvement and the net reclassification improvement.
A P<0.05 was accepted as statistically significant. Statistical analyses were performed using SPSS 22.0 for Windows (SPSS, Inc, Chicago, IL), survIDINRI package for R v. 3.3.1 for Windows, and GraphPad Prism 3.3 (GraphPad Software, Inc, La Jolla, CA).
Results cfDNA Correlates With Age
We performed cfDNA measures in plasma from 127 healthy subjects and 686 AF patients. As shown in Figure 1 , we found that there is a significant increase in cfDNA in subjects >75 years of age. To avoid any bias, we only included subjects aged <75 years in later studies (controls: n=100, 33% female, median age: 54 years [IQR, 50-60]; AF patients: n=336 patients, 38% female, median age: 69 years [IQR, 63-72]).
Patients' Clinical, Demographic, and Genetic Characteristics
Demographic and clinical characteristics of the patient cohort are shown in Table 1 . The median CHA 2 DS 2 -VASc score was 3 (IQR, 2-4), and 84.8% of patients had a CHA 2 DS 2 -VASc score ≥2. Additionally, all patients were stable on acenocoumarol treatment for at least 6 months before recruitment. The time in therapeutic range 6 months after inclusion was 80% (IQR, 66-100). The median follow-up was 7.9 years (IQR, 7.3-8.1). During this period, we recorded 47 composites of cardiovascular events (14.0%, annual rate: 1.77% per year), 27 ischemic strokes Figure 1 . Plasma cell-free DNA (cfDNA) is associated with age in controls and atrial fibrillation (AF) patients. cfDNA was measured using Sytox green as described in the Materials and Methods section. Results from rs2431697 genotyping are shown in Table 1 . No deviation from the Hardy-Weinberg equilibrium was observed (P=0.470).
cfDNA and NE in Plasma Samples
In 100 healthy subjects, we found a mean cfDNA of 54.4±1.95 ng/mL. This value was significantly lower than that found in the plasma of AF patients (73.7±2.75 ng/mL; P<0.001; Figure  IA in the online-only Data Supplement).
In addition, NE was also higher in the patients' plasma in comparison to the plasma of healthy subjects (48.05±2.07 versus 32.92±2.43 ng/mL, respectively; P<0.001; Figure IB in the online-only Data Supplement).
Of note, we found a significant positive correlation between cfDNA and NE values in AF patients (Spearman ρ=0.281; P<0.001; Figure IC in the online-only Data Supplement).
cfDNA and NE as Predictors of ACEs
For evaluating the relationship between cfDNA and NE plasma levels with the occurrence of ACEs in AF patients, we used the cutoff points calculated by ROC curves: cfDNA >92 ng/mL and NE >55.29 ng/mL.
Although univariate Cox regression analyses demonstrated that cfDNA levels were not associated with a higher risk of ACEs in patients, this analysis showed a significant increased risk of ACEs for NE levels. According to these analyses, an NE level >55.29 ng/mL was associated with a higher risk of all-cause mortality (P<0.001), cardiovascular mortality (P=0.020), composite cardiovascular events (P=0.005), and ischemic stroke (P=0.009; Table 2 ).
To determine the independent effect of clinical risk factors and NE on the risk of ACEs, we performed subsequent multivariate Cox regression analyses. Thus, NE levels >55.29 ng/mL were independently associated with a higher risk of all-cause mortality (hazard ratio, 2.24; 95% CI, 1.36-3.68), cardiovascular mortality (hazard ratio, 4.77; 95% CI, 1.11-20.47), and the composite of cardiovascular events (hazard ratio, 1.84; 95% CI, 1.01-3.76; Table 3 ).
For ischemic stroke, only age and previous stroke demonstrated a significant association, whereas NE did not (Table 3) .
Kaplan-Meier survival curves clearly showed that higher NE levels were associated with lower time to event for allcause and cardiovascular mortality and for the composite of cardiovascular events (Figure 2 ).
Additive Effect of NE Levels to Clinical Risk Scores
We also investigated whether NE levels could improve risk stratification in AF patients. Thus, we included NE in the CHA 2 DS 2 -VASc score, which is the most widely used risk score for predicting thromboembolic events in AF. The C indexes for the 4 events evaluated were enhanced, and the modified CHA 2 DS 2 -VASc score was demonstrated to significantly predict all-cause mortality (0.628; 95% CI, 0.574-0.680; P=0.001), cardiovascular events (0.675; 95% CI, 0.622-0.725; P<0.001), and ischemic stroke (0.716; 95% CI, 0.665-0.764; P<0.001; Table 4; Figure 3) . However, the comparison of ROC curves did not show a significant higher predictive ability of the CHA 2 DS 2 -VASc+NE versus the original CHA 2 DS 2 -VASc (Table 4 ).
Additionally, we tested the sensitivity and reclassification of using the integrated discriminatory improvement and net reclassification improvement analyses. Overall, the CHA 2 DS 2 -VASc+NE score showed nonsignificant higher sensitivity and positive reclassification for cardiovascular mortality, cardiovascular events, and ischemic stroke compared with the original CHA 2 DS 2 -VASc score. Nevertheless, we 
Relationship Between rs2431697 and NE in Healthy Subjects and in AF Patients
We did not find a significant association between the rs2431697 genotype and NE levels in healthy subjects ( Figure IIA in the online-only Data Supplement). In AF patients, NE levels of CC homozygous (n=63) were significantly lower than those of T allele carriers (n=252; 40.01±3.05 versus 51.82±2.73 ng/ mL, respectively; P=0.040; Figure IIB in the online-only Data Supplement). In addition, among patients with the highest NE values (>55.29 ng/mL), we found a frequency almost 2-fold higher in subjects bearing the T allele (29%) than for C homozygotes (13%; P=0.008; Table 5 ).
miR-146a Genotype Conditions NET Formation
Human neutrophils from 14 healthy donors were isolated (TT=7 and CC=7). As expected, miR-146a expression levels in neutrophils from T allele carriers were ≈40% lower than those from homozygous C carriers, although these results were not statistically significant, probably because of the small sample size ( Figure III in the online-only Data Supplement). To investigate whether rs2431697 impacts NETosis, we further activated neutrophils with phorbol-12-myristate-13-acetate. The results of DNA shed from seeded neutrophils are shown in Figure 4A . After activation with phorbol-12-myristate-13-acetate, neutrophils of TT homozygous subjects had a higher relative increase in DNA than CC subjects ( Figure 4A ). Next, we quantified the expression of H3cit by indirect immunofluorescence as a specific marker of NETosis. Again, we found a relationship between rs2431697 genotype and H3cit expression. As shown ( Figure 3B through 3D), the ratio of H3cit-positive cells/total cells was markedly higher in neutrophils from TT subjects in comparison to CC subjects (5.15±0.51% versus 1.21±0.15%, respectively; P<0.001). 
Absence of MiR-146a in Murine Neutrophils Increases NET Formation
After activation with phorbol-12-myristate-13-acetate, miR146a −/− neutrophils (n=7/genotype) had a higher relative increase in DNA than WT mice (3.67±0.34 ng/µL versus 2.84±0.28 ng/µL; P<0.05; Figure 5A ). Next, we quantified the expression of H3c by indirect immunofluorescence as a specific marker of NETosis. The ratio of H3c-positive cells/total cells were markedly higher in neutrophils from miR-146a −/− mice in comparison to their WT littermates (5.14±0.33% versus 3.21±0.26%, respectively; P<0.001; Figure 5B through 5D).
Discussion
Our results revealed that NETosis is a new component of the inflammatory background and atherothrombosis underlying AF. 23, 24 These findings suggest that high NE levels could even delimit an inflammatory burden before arrhythmia. Thus, we found that patients with higher vWF and interleukin (IL)-6 values also had the highest NE plasma levels. If one of these elements precedes the others, it is difficult to define, but all of them count for the nexus between inflammation and AF argued in recent years as a result of observational and ex vivo clinical studies. 23 For its part, cfDNA levels in patients with AF proved not to be associated with ACEs. Notwithstanding, cfDNA is a nonspecific NETosis marker as it is mainly derived from non-neutrophil dead cells, 25 whereas NE quantification is currently considered one of the most specific, objective, and quantitative assay to monitor NETosis. 26 Studies have shown that, besides cytokines, NETosis markers are subrogated proinflammatory and prognostic factors in several cardiac pathologies. 16, 17, [27] [28] [29] [30] In fact, NE has been shown to be elevated in human atherosclerotic plaque shoulders. 31 More recently, NET burden has been associated with the resolution of the ST-segment and myocardial infarct size. 17 Mechanistically, it has been shown that high levels of NE regulate the IL-1β release from the endothelium, which is related to inflammatory cardiovascular disease. 32 Here, we show that NET components are also new prognostic markers for ACEs in AF patients. Therefore, the combination of high NE levels with other comorbidities often experienced by AF patients, such as coronary microvascular dysfunction of hypertension, diabetes mellitus, chronic heart failure, and left ventricular hypertrophy, 33 might help to reach an inflammatory threshold that leads to ACEs. It is well known that not all AF patients have the same risk for an ACE, not even those patients with the same CHA 2 DS 2 -VASc score. Moreover, the pathogenic mechanisms of the end points considered in this study also differ between patients. Interestingly, patients who experience stroke (n=27), generally a thromboembolic end point, had higher NE values than the other patients (41. P=0.340), although these differences were not statistically significant. The low number of patients with stroke in the study population did not allow us to draw any conclusion about this issue, which should, therefore, be explored further in future studies.
The role of biomarkers in the prediction of ACEs has been extensively investigated and their value in the everyday real-world clinical evaluation of AF patients is debated. 34, 35 Thus, the clinical use of adding a biomarker to clinical scores remains limited given the marginal net benefit, especially after long-term follow-up. 36 In the present study, after adding NE, the predictive ability for all-cause mortality, cardiovascular mortality, cardiovascular events, and ischemic stroke was slightly increased, although it was not significantly different from the original CHA 2 DS 2 -VASc score. Thus, adding NE as a biomarker did not improve this clinical risk score. In a recent report, we showed that the addition of other biomarkers enhanced the predictive value of CHA 2 DS 2 -VASc and HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/ alcohol concomitantly, age) score, but the addition provided only a modest overall improvement, and marginal added predictive advantage over the original scores. 37 However, the present study has demonstrated that NE was independently associated with a higher risk of cardiovascular events, cardiovascular mortality, and all-cause mortality in these patients. This fact is clinically relevant, and because this study included a cohort of young AF patients (<75 years), future studies are needed to further investigate this association.
MiRNAs have been recognized as new components of the pathological processes of cardiovascular diseases. [38] [39] [40] In particular, our group demonstrated the association of miR-146a with a higher risk of ACEs in AF patients bearing the T variant of rs2431697. 8 However, to date, a relationship between miRNAs and NETosis has not been described. Here, we give further molecular clues to the association between rs2431697 and the occurrence of ACEs. Thus, our in vitro results show that the inflammatory stimulus delimitates differences in the susceptibility to NETosis driven by rs2431697. In this manner, we suggest that rs2431697 may be associated with NE levels in patients with AF, thus promoting a higher rate of ACE occurrence.
Our results from WT and miR-146a −/− murine neutrophils point to a causal relationship between miR-146a and NETosis. However, the mechanism behind the action of miR-146a is still unknown. MiRNAs work by binding to mRNA and inhibiting their translation. It has been described that NET production is independent of the expression of de novo genes; in other words, neutrophils already contain all the necessary factors for the formation of NETs when they leave the bone marrow. 41 Therefore, miR-146a must play its role before cell activation. It has been demonstrated that a lack of miR-146a targets in mice, such as TLR4, prevents NET formation. 42 Moreover, it has been shown in a mouse model that NET components increase with aging. 30 Therefore, we speculate that lower levels of miR-146a because of rs2431697 will also contribute to NETosis by a mechanism that is yet to be identified. Consequently, this genotype may contribute to age-related inflammation leading to atherosclerosis and the progression of cardiovascular diseases. 43 Several preclinical therapies for preventing atherosclerosis and its harmful effects are already underway. Some of these therapies are focused on reducing as much of the NETosis process as possible, and they consist of pharmacological or genetic tools that degrade DNA or inhibit histone citrullination or of enzymes that interfere with the respiratory chain, leading to ROS clearance or enhancing NET clearance. All these strategies are meant to cause a decrease in NET release and to control their detrimental consequences. 44, 45 Our results suggest that miR-146a could play a valuable role in complementing these therapies as its increase has been shown to be beneficial in inhibiting atherosclerosis. 46, 47 Further studies are needed to assess the role of NETs and miR-146a in patients with AF and to test their therapeutic usefulness in this disease and other inflammatory diseases.
Limitations of the Study
There are some limitations regarding this study that we must acknowledge. First, it was performed in a single center, and it composed of a white-based population. Second, all AF patients had good anticoagulation control during the previous 6 months after entry, to guarantee that the impact of the biomarkers was not related to poor anticoagulation control. Additionally, we selected patients who were anticoagulated according to their CHA 2 DS 2 -VASc score. Therefore, our results should only be extrapolated to clinically similar patients. Whether NET compounds are prognostic markers of ACEs in AF patients without comorbidities is an interesting issue not explored in our study but that deserves further investigation.
We have measured the NET formation in samples at diagnosis, and no other determinations have been performed throughout the 7.9-year follow-up. How the predictor factors for ACEs identified here evolve throughout the followup period has not been determined. Because comorbidities change over time, we expect that biomarkers will also change. However, because our aim was to find factors with the ability to predict ACEs during a long follow-up, we remain confident in our results.
In recent years, the neutrophil/lymphocyte ratio has been associated with inflammation and worse outcomes in patients with cardiovascular diseases. It would have been timely to analyze the association between neutrophil/lymphocyte ratio and ACEs and the rs2431697 genotype in our series. However, 8 years ago, analytic data were not computerized in our hospital, and we have been unable to perform such analyses. In addition, we cannot rule out that other causes than NETosis such as neutrophil degranulation or a higher neutrophil count may also be behind the high levels of plasma NE in patients with ACEs. Additional studies are needed to establish the relationship between the rs2431697 genotype and the risk of ACEs in AF patients.
